PHILADELPHIA, Pennysylvania and DUBLIN, Ireland, October 29 /PRNewswire/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to September 30, 2008.
Q3 2008 Financial Highlights
- Product sales up 31% to $713 million - Product sales excluding ADDERALL XR(R) up 51% to $444 million - New product sales(1) $276 million, 39% of product sales (2007: 22%) - Total revenues up 28% to $779 million - Non GAAP earnings(2) per ADS up 88% to $1.17 (2007: $0.62) - US GAAP earnings(2) per ADS down 62% to $0.07 (2007: $0.19)
(1) New product sales comprise DAYTRANA(R), ELAPRASE(R), FIRAZYR(R), FOSRENOL(R), LIALDA(R) / MEZAVANT(R) and VYVANSE(R)
(2) Earnings from continuing operations